Related Experiment Videos
Multidrug-resistant tuberculosis in Denmark 1993-1995
1Clinic of Pulmonary Medicine, RHIMA Center, University Hospital, p4penhagen, Denmark.
Summary
Multidrug-resistant tuberculosis (MDR-TB) is rare in Denmark, affecting less than 1% of cases. While treatment is lengthy and costly, patients can be cured with specialized drug regimens.
Area of Science:
- Microbiology
- Infectious Diseases
- Public Health
Background:
- Tuberculosis (TB) remains a significant global health challenge.
- The emergence of multidrug-resistant tuberculosis (MDR-TB) poses a threat to effective treatment.
- Understanding the incidence and characteristics of MDR-TB is crucial for public health strategies.
Purpose of the Study:
- To investigate the incidence, treatment outcomes, and prognosis of MDR-TB cases in Denmark.
- To analyze the characteristics of patients infected with multidrug-resistant Mycobacterium tuberculosis.
- To evaluate the effectiveness of treatment regimens for MDR-TB.
Main Methods:
- Retrospective analysis of routine data on bacteriologically confirmed tuberculosis cases in Denmark.
- Identification and characterization of multidrug-resistant tuberculosis cases between 1993 and 1995.
- Evaluation of treatment regimens and patient outcomes.
Main Results:
- Nine cases of MDR-TB were identified among 1354 tuberculosis cases (less than 1%) between 1993-1995.
- All identified MDR-TB cases were acquired outside of Denmark.
- Eight out of nine patients responded favorably to treatment with pyrazinamide, streptomycin or amikacin, ofloxacin, and cycloserine, sometimes supplemented with other drugs.
Conclusions:
- MDR-TB is uncommon in Denmark but requires careful monitoring due to imported cases.
- Successful treatment of MDR-TB is possible but necessitates prolonged hospitalization and observed treatment.
- The treatment process for MDR-TB is lengthy and expensive, highlighting the need for efficient management strategies.